Delcath Systems Inc
Delcath Systems Inc (DCTH) is a healthcare company focused on targeted regional delivery of chemotherapy to the liver. Its technology is designed to isolate the liver’s blood supply temporarily, allowing higher doses of melphalan to be administered directly to tumours while limiting systemic exposure. Investors should note the company operates in a clinical‑oriented, capital‑intensive segment where regulatory decisions, trial outcomes and reimbursement dynamics can strongly affect valuation. With a market cap of approximately $398.26M, Delcath sits at a size where financing, commercial adoption and execution risk are meaningful considerations. The stock may appeal to investors interested in specialised oncology therapies, but it carries higher risk than large diversified healthcare companies. This is educational information and not personalised financial advice; values can rise and fall and past performance is not a guide to future results.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Delcath Systems' stock with a target price of $21.88, indicating strong growth potential.
Financial Health
Delcath Systems is generating solid revenue and high profit margins, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DCTH
Next-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Targeted Oncology Approach
Delcath’s hepatic delivery tech concentrates chemotherapy in the liver, which could improve local control — though clinical and regulatory outcomes remain uncertain.
Clinical & Regulatory Focus
Trial results and approvals are key value drivers; setbacks or delays can materially affect the share price, so monitor updates closely.
Commercial & Financing Risks
Small market cap means growth depends on adoption, reimbursement and access to capital; funding needs can dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
